Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Sensorion    ALSEN   FR0012596468

SENSORION

(ALSEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Growth Paris
02/25/2021 02/26/2021 03/01/2021 03/02/2021 03/03/2021 Date
2.14(c) 2.12(c) 2.24(c) 2.23(c) 2.13(c) Last
213 840 94 992 142 893 141 935 140 967 Volume
0.00% -0.93% +5.66% -0.45% -4.48% Change
More quotes
Financials
Sales 2020 3,65 M 4,40 M 4,40 M
Net income 2020 -15,9 M -19,1 M -19,1 M
Net Debt 2020 - - -
P/E ratio 2020 -9,26x
Yield 2020 -
Sales 2021 3,40 M 4,10 M 4,10 M
Net income 2021 -20,5 M -24,7 M -24,7 M
Net Debt 2021 - - -
P/E ratio 2021 -7,61x
Yield 2021 -
Capitalization 163 M 197 M 197 M
Capi. / Sales 2020 44,8x
Capi. / Sales 2021 48,1x
Nbr of Employees 24
Free-Float 73,9%
More Financials
Company
Sensorion specializes in the research and development of medicines for the treatment of inner ear disorders (dizziness or loss of balance, hearing problems, tinnitus, etc.). At the end of 2019, the company has a portfolio of 2 products in Phase II clinical development (SENS-111 for the treatment of acute attack of vertigo, and SENS-401 for the protective treatment of internal ear tissue in case of lesional attacks). 
More about the company
All news about SENSORION
02/19SENSORIONá : Presents New Preclinical Data on SENS-401 at ARO 2021
BU
02/17SENSORIONá : Announces That an Extraordinary General Meeting Will Be Held Behind..
BU
02/17SENSORIONá : A Chardan Top Pick for 2021
BU
02/16SENSORIONá : Adds New Gene Therapy Target to Development Portfolio to Address He..
MT
02/15SENSORIONá : announces third gene therapy collaboration with Institut Pasteur ta..
PU
02/15SENSORIONá : Letter to Shareholders - 2021.
PU
02/15SENSORIONá : announces preclinical data demonstrating SENS-401's potential to pr..
PU
02/15SENSORIONá : Half-year report on the Sensorion liquidity contract with Kepler Ch..
PU
02/01SENSORIONá : Letter to Shareholders - 2021. Read
PU
02/01SENSORIONá : Corporate presentation
PU
01/19SENSORIONá : Says SENS-401 Product Reduces Loss of Residual Hearing; Shares Rise..
MT
01/19SENSORIONá : announces preclinical data demonstrating SENS-401's potential to pr..
PU
01/19SENSORIONá : Announces Preclinical Data Demonstrating SENS-401's Potential to Pr..
BU
01/18SENSORIONá : Half-year report on the Sensorion liquidity contract with Kepler Ch..
PU
01/18SENSORIONá : Half-year report on the Sensorion liquidity contract with Kepler Ch..
BU
More news
News in other languages on SENSORION
02/19SENSORIONá : présente des nouvelles données précliniques sur le SENS-401 à l'ARO..
02/17SENSORIONá : annonce la tenue à huis clos d'une Assemblée Générale Extraordinair..
02/17SENSORIONá : Avis de réunion - 17 février 2021
02/17SENSORIONá : Un Top Pick en 2021 pour Chardan
02/16Londres et Paris dopées aux vaccins, aux cycliques et à Vivendi
More news
Chart SENSORION
Duration : Period :
Sensorion Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SENSORION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 4,77 €
Last Close Price 2,13 €
Spread / Highest target 229%
Spread / Average Target 124%
Spread / Lowest Target 7,98%
EPS Revisions
Managers and Directors
NameTitle
Nawal Ouzren Chief Executive Officer & Director
Edwin Moses Chairman
GÚraldine Honnet Chief Medical Officer
Eric Forquenot de La Fortelle Independent Director
Julien Miara Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SENSORION42.00%207
MODERNA, INC.40.53%58 690
LONZA GROUP AG1.62%46 935
IQVIA HOLDINGS INC.6.37%36 961
CELLTRION, INC.-15.60%35 341
SEAGEN INC.-15.54%27 847